Oryzon Gets EMA Nod to Test Vafidemstat in Phelan-McDermid Syndrome

  • EMA approved Oryzon’s Phase II HOPE-2 study for vafidemstat in Phelan-McDermid Syndrome (PMS).
  • Study will enroll 12 adult PMS patients, focusing on safety, anger/aggression reduction, and overall disease efficacy.
  • HOPE-2 is partially funded through Oryzon’s VANDAM project under Med4Cure, an IPCEI on Health.
  • Vafidemstat is the only LSD1 inhibitor in clinical development for CNS disorders.

Oryzon’s EMA approval for the HOPE-2 study positions vafidemstat as a potential first-in-class treatment for Phelan-McDermid Syndrome, a rare neurodevelopmental disorder with no approved therapies. The study’s success could validate Oryzon’s epigenetic modulation approach in genetically defined CNS patient populations, potentially unlocking broader applications in other neurodevelopmental syndromes. The partial funding through Med4Cure underscores the strategic importance of this project within the EU’s health innovation framework.

Clinical Efficacy
Whether vafidemstat can demonstrate meaningful improvements in aggression and overall disease severity in PMS patients.
Regulatory Pathway
The pace at which Oryzon can advance vafidemstat through subsequent clinical phases given the orphan disease designation potential.
Competitive Positioning
How Oryzon’s LSD1 inhibitor strategy differentiates it in the crowded CNS epigenetic drug space.